Vaxcyte, Inc. today announced that the first participants received injections in a Phase 1/2 clinical study of VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent pneumococcal conjugate vaccine (PCV) in adults. Invasive pneumococcal disease (IPD).
Vaxcute said it expects to release topline data from the Phase 1/2 study in the second half of 2024.
“We are pleased to initiate the first adult clinical study of VAX-31, the broadest-spectrum PCV entering the clinic with the potential to prevent approximately 95% of IPD in U.S. adults,” said Grant Pickering, CEO and Co-Founder of Vaxcyte People, in a press release dated November 9, 2023.
“Leveraging the foundation established with our lead PCV candidate VAX-24, we believe we have the opportunity to deliver a best-in-class PCV franchise that provides the broadest coverage and improved immune response compared to standard of care today. of adults.”
The VAX-31 Phase 1/2 clinical study is a randomized, observer-blinded, active-controlled, dose-finding clinical study designed to evaluate the safety and tolerability of VAX-31 compared with Prevnar 20® in healthy older adults. Sexuality and Immunogenicity 50 years and older.
Pneumococcal disease (PD) is an infection caused by Streptococcus pneumoniae. It can cause IPD, including meningitis and bacteremia, and non-invasive PD, including pneumonia, otitis media, and sinusitis.
The National Center for Health Statistics Mortality Surveillance reported on October 27, 2023 that most recent respiratory disease deaths have been related to pneumonia, not COVID-19 or influenza. More PCV vaccine and candidate news from Precision Vax.
The Centers for Disease Control and Prevention (CDC) pneumococcal vaccine schedule updated in 2023.